Skip to main content

Prevalence, treatment, and control of severe hyperlipidemia.

Publication ,  Journal Article
Gold, ME; Nanna, MG; Doerfler, SM; Schibler, T; Wojdyla, D; Peterson, ED; Navar, AM
Published in: American journal of preventive cardiology
September 2020

To identify the prevalence, treatment, and low-density lipoprotein cholesterol (LDL-C) control of individuals with LDL-C ≥190 ​mg/dL in contemporary clinical practice.We included adults (age ≥18 years) with LDL-C ≥190 ​mg/dL, at least one LDL-C level drawn from 255 health systems participating in Cerner HealthFacts database (2000-2017, n ​= ​4,623,851), and a detailed examination within Duke University Health System (DUHS, 2015-2017, n ​= ​267,710). Factors associated with LDL-C control were evaluated using multivariable logistic regression modeling.The cross-sectional prevalence of LDL-C ≥190 ​mg/dL was 3.0% in Cerner (n ​= ​139,539/4,623,851) and 2.9% at DUHS (n ​= ​7728/267,710); among these, rates of repeat LDL-C measurement within 13 months were low: 27.9% (n ​= ​38,960) in Cerner, 54.5% (n ​= ​4211) at DUHS. Of patients with follow-up LDL-C levels, 23.6% in Cerner had a 50% of greater reduction in LDL-C, 18.3% achieved an LDL-C <100 ​mg/dL and 2.7% ​< ​70 ​mg/dL. At DUHS, 28.4% had a 50% or greater reduction in LDL-C, 28.4% achieved an LDL-C ≤100 ​mg/dL and 4.4% achieved <70 ​mg/dL. Within DUHS, 71.6% with LDL-C ≥190 ​mg/dL were on any statin during follow-up, but only 28.5% were on a high-intensity statin. In multivariable modeling, seeing a cardiologist (Cerner odds ratio [OR] 1.56, confidence interval [CI] 1.33-1.83; DUHS OR 1.89, 95% CI 1.18-3.01) and having diabetes (Cerner OR 1.34 CI 1.23-1.46; DUHS OR 2.07, CI 1.62-2.65) increased odds of LDL-C control, defined as a ≥50% reduction in LDL-C (at Cerner) or initiation of high intensity statin (at DUHS). Prior atherosclerotic cardiovascular disease (OR 1.19, CI 1.07-1.33), hypertension (OR 1.10, CI 1.03-1.18), African American race (OR 0.79, CI 0.71-0.89), and government (vs. private) insurance (OR 0.90, CI 0.83-0.98) were associated with LDL-C control at Cerner. Female sex was associated with lower odds of appropriate therapy (OR 0.69, CI 0.59-0.81) at DUHS.Approximately 3% of United States adults have LDL-C ≥190 ​mg/dL. Among those with very high LDL-C, rates of repeat measurement within one year were low; of those retested, only about one-fourth met guideline-recommended LDL-C treatment goals.

Duke Scholars

Published In

American journal of preventive cardiology

DOI

EISSN

2666-6677

ISSN

2666-6677

Publication Date

September 2020

Volume

3

Start / End Page

100079

Related Subject Headings

  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gold, M. E., Nanna, M. G., Doerfler, S. M., Schibler, T., Wojdyla, D., Peterson, E. D., & Navar, A. M. (2020). Prevalence, treatment, and control of severe hyperlipidemia. American Journal of Preventive Cardiology, 3, 100079. https://doi.org/10.1016/j.ajpc.2020.100079
Gold, Matthew E., Michael G. Nanna, Shannon M. Doerfler, Tony Schibler, Daniel Wojdyla, Eric D. Peterson, and Ann Marie Navar. “Prevalence, treatment, and control of severe hyperlipidemia.American Journal of Preventive Cardiology 3 (September 2020): 100079. https://doi.org/10.1016/j.ajpc.2020.100079.
Gold ME, Nanna MG, Doerfler SM, Schibler T, Wojdyla D, Peterson ED, et al. Prevalence, treatment, and control of severe hyperlipidemia. American journal of preventive cardiology. 2020 Sep;3:100079.
Gold, Matthew E., et al. “Prevalence, treatment, and control of severe hyperlipidemia.American Journal of Preventive Cardiology, vol. 3, Sept. 2020, p. 100079. Epmc, doi:10.1016/j.ajpc.2020.100079.
Gold ME, Nanna MG, Doerfler SM, Schibler T, Wojdyla D, Peterson ED, Navar AM. Prevalence, treatment, and control of severe hyperlipidemia. American journal of preventive cardiology. 2020 Sep;3:100079.

Published In

American journal of preventive cardiology

DOI

EISSN

2666-6677

ISSN

2666-6677

Publication Date

September 2020

Volume

3

Start / End Page

100079

Related Subject Headings

  • 3201 Cardiovascular medicine and haematology